Stock Views on Ranbaxy Laboratories, Rain Commodities, Lupin

Angel Broking on Ranbaxy Laboratories - Target of Rs 500


Angel Broking has maintained its buy rating on Ranbaxy Laboratories with a target of Rs 500 in its September 18, 2008 research report. "we remain positive on Ranbaxy in the long term and maintain a Buy on the stock with a SOTP Target Price of Rs 500, wherein the core business fetches Rs 365 and Rs 135 would account for the FTF opportunities and cash lying on the Balance Sheet," says Angel Brokings' research report.



PINC Research on Rain Commodities - Target of Rs 300


PINC Research has recommended a buy rating on Rain Commodities with 12-month target of Rs 300 in its September 29, 2008 research report. "At the CMP of Rs 186, the stock trades at an EV/EBIDT and P/E of 4.3x and 2.8x its CY09E earnings. We expect the strong predictability of demand & margins, coupled with visibility of revenues and the operating leverage of the company’s business model to enable it to capitalise on the trend of pricing advantage moving in favour of CPC manufacturers. Hence, we initiate coverage with a ‘BUY’ recommendation, with a price target of Rs 300 on an investment horizon of 12 months," says PINC's research report.



Motilal Oswal on Lupin - Target of Rs 933


Motilal Oswal has maintained its buy rating on Lupin with a target of Rs 933 in its September 23, 2008. "Lupin is currently valued at 15.1x FY09E and 11.3x FY10E core earnings. We believe that the stock has the potential of getting rerated given the differentiated business model of the company. If the current INR v/s the USD rate sustains (@ Rs 46/USD), we expect an upside to our estimates. We reiterate Buy with a price target of Rs 933 (28% upside). Earlier-than-expected competition for Suprax (in US) and significant currency appreciation, are the key risks to our positive stance," says Motilal Oswal's research report.